Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats

被引:246
作者
Feldman, David L. [1 ]
Jin, Liang [1 ]
Xuan, Hong [1 ]
Contrepas, Aurelie [2 ,3 ]
Zhou, Yinong [1 ]
Webb, Randy L. [1 ]
Mueller, Dominik N. [4 ]
Feldt, Sandra [4 ]
Cumin, Frederick [1 ]
Maniara, Wieslawa [1 ]
Persohn, Elke [5 ]
Schuetz, Helmut [5 ]
Danser, A. H. Jan [6 ]
Nguyen, Genevieve [2 ,3 ]
机构
[1] Novartis Inst Biomed Res, E Hanover, NJ 07936 USA
[2] INSERM, U833, Paris, France
[3] Coll France, Chaire Med Expt, F-75231 Paris, France
[4] Max Delbruck Ctr Mol Med, Berlin, Germany
[5] Novartis Pharma AG, Basel, Switzerland
[6] Erasmus MC, Dept Pharmacol, Rotterdam, Netherlands
关键词
aliskiren; renin inhibitor; TG(mRen-2)rat; diabetic nephropathy; (pro)renin receptor;
D O I
10.1161/HYPERTENSIONAHA.107.108845
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The aim of this study was to explore the effects of the renin inhibitor aliskiren in streptozotocin-diabetic TG(mRen-2)27 rats. Furthermore, we investigated in vitro the effect of aliskiren on the interactions between renin and the (pro)renin receptor and between aliskiren and prorenin. Aliskiren distributed extensively to the kidneys of normotensive (non) diabetic rats, localizing in the glomeruli and vessel walls after 2 hours exposure. In diabetic TG(mRen-2)27 rats, aliskiren (10 or 30 mg/kg per day, 10 weeks) lowered blood pressure, prevented albuminuria, and suppressed renal transforming growth factor-beta and collagen I expression versus vehicle. Aliskiren reduced (pro)renin receptor expression in glomeruli, tubules, and cortical vessels compared to vehicle (in situ hybridization). In human mesangial cells, aliskiren (0.1 mu mol/L to 10 mu mol/L) did not inhibit binding of (125)I-renin to the (pro)renin receptor, nor did it alter the activation of extracellular signal-regulated kinase 1/2 by renin (20 nmol/L) preincubated with aliskiren (100 nmol/L) or affect gene expression of the (pro)renin receptor. Evidence was obtained that aliskiren binds to the active site of prorenin. The above results demonstrate the antihypertensive and renoprotective effects of aliskiren in experimental diabetic nephropathy. The evidence that aliskiren can reduce in vivo gene expression for the (pro)renin receptor and that it may block prorenin-induced angiotensin generation supports the need for additional work to reveal the mechanism of the observed renoprotection by this renin inhibitor. (Hypertension. 2008;52:130-136.)
引用
收藏
页码:130 / 136
页数:7
相关论文
共 29 条
[1]   Interactions of transforming growth factor-β and angiotensin II in renal fibrosis [J].
Border, WA ;
Noble, NA .
HYPERTENSION, 1998, 31 (01) :181-188
[2]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[3]   Elevated blood pressure and heart rate in human renin receptor transgenic rats [J].
Burcklé, CA ;
Danser, AHJ ;
Müller, DN ;
Garrelds, IM ;
Gasc, JM ;
Popova, E ;
Plehm, R ;
Peters, J ;
Bader, M ;
Nguyen, G .
HYPERTENSION, 2006, 47 (03) :552-556
[4]   Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL [J].
de Zeeuw, D ;
Remuzzi, G ;
Parving, HH ;
Keane, WF ;
Zhang, ZX ;
Shahinfar, S ;
Snapinn, S ;
Cooper, MF ;
Mitch, WE ;
Brenner, BM .
KIDNEY INTERNATIONAL, 2004, 65 (06) :2309-2320
[5]  
DERKX FHM, 1992, J BIOL CHEM, V267, P22837
[6]   Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients [J].
Gradman, AH ;
Schmieder, RE ;
Lins, RL ;
Nussberger, J ;
Chiang, YT ;
Bedigian, MP .
CIRCULATION, 2005, 111 (08) :1012-1018
[7]   Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells [J].
Huang, Y. ;
Noble, N. A. ;
Zhang, J. ;
Xu, C. ;
Border, W. A. .
KIDNEY INTERNATIONAL, 2007, 72 (01) :45-52
[8]   Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms [J].
Huang, Y ;
Wongamorntham, S ;
Kasting, J ;
McQuillan, D ;
Owens, RT ;
Yu, L ;
Noble, NA ;
Border, W .
KIDNEY INTERNATIONAL, 2006, 69 (01) :105-113
[9]   Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle'' region for nonproteolytic activation of prorenin [J].
Ichihara, A ;
Hayashi, M ;
Kaneshiro, Y ;
Suzuki, F ;
Nakagawa, T ;
Tada, Y ;
Koura, Y ;
Nishiyama, A ;
Okada, H ;
Uddin, MN ;
Nabi, AHMN ;
Ishida, Y ;
Inagami, T ;
Saruta, T .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (08) :1128-1135
[10]   Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice [J].
Ichihara, Atsuhiro ;
Suzuki, Fumiaki ;
Nakagawa, Tsutomu ;
Kaneshiro, Yuki ;
Takemitsu, Tomoko ;
Sakoda, Mariyo ;
Nabi, A. H. M. Nurun ;
Nishiyama, Akira ;
Sugaya, Takeshi ;
Hayashi, Matsuhiko ;
Inagami, Tadashi .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (07) :1950-1961